Mediaboss Marketing

PRESS RELEASE: MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

DGAP-News: MOLOGEN AG / Key word(s): Study MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

03.02.2014 / 09:07

=--------------------------------------------------------------------

MOLOGEN AG: Final results from renal cancer trial with MGN1601 presented at ASCO Genitourinary Cancers Symposium

- Treatment with MGN1601 safe and well tolerated

- Promising median overall survival data in a subgroup of patients

- Presentation at ASCO - GU attracted great interest

Berlin, February 3, 2014 - Final results from the phase I/II clinical study with MGN1601 (ASET trial) have been presented in a poster at the 2014 Genitourinary Cancers Symposium. The trial evaluated safety and tolerability of MGN1601 in 19 heavily pretreated patients with advanced renal cancer which had no other treatment options. The monotherapy with tumor cell-based cancer vaccine MGN1601 was well tolerated and safe. Furthermore, treatment with MGN1601 resulted in promising median overall survival data in a subgroup of patients. One patient achieved a long term partial response and another patient up to 60 weeks with disease control. Putative predictive biomarkers were identified from pre-treatment characteristics, which were associated with longer overall survival. Those may allow identifying patients more likely to benefit from this innovative vaccination approach with MGN1601.

In total 19 patients were included into the study and received at least one MGN1601 injection (ITT population). 10 patients completed the study per protocol (PP population). 9 patients discontinued the study early without completing the planned treatment phase due to the worsening of their tumor disease (non-PP population).

Original post:
PRESS RELEASE: MOLOGEN AG: Final results from -2-